- Tenet Healthcare Corp's THC shares are gaining Tuesday morning following its Street-beating first quarter FY23 performance and raised FY23 outlook.
- THC Q1 FY23 adjusted EPS came in at $1.42, down from $1.90 a year ago and beating the consensus of $1.15.
- The net operating revenue of the multinational healthcare services company reached $5.02 billion, up 5.8% Y/Y, beating the consensus of $4.85 billion.
- Hospital segment sales rose 2.7% to $3.89 billion due to increased adjusted admissions, partially offset by lower COVID-related volume and acuity.
- Ambulatory segment revenues increased 22.6% to $905 million, driven by same-facility solid net surgical case growth, acquisitions and opening of new facilities, service line growth, and improved pricing yield.
- Conifer Segment sales were majorly flat on year to $324 million.
- Adjusted EBITDA slumped 6.3% to $832 million from $888 million a year ago.
- Net income reached $143 million, up from $139 million last year.
- Outlook: Tenet forecasts Q2 FY23 sales of $4.8 billion - $5 billion (consensus $4.91 billion).
- It expects an adjusted EPS of $1.07 - $1.30 (consensus $1.16).
- For FY23, the company raised its sales guidance from $19.70 billion - $20.10 billion to $19.80 billion - $20.20 billion versus the Street view of $20.04 billion.
- THC raised its adjusted EPS forecast from $4.68 - $5.85 to $4.92 - $6.09, against the consensus of $5.43.
- Price Action: THC shares are 5.5% higher at $72.81 during the premarket trading session on Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: EarningsEquitiesNewsGuidanceHealth CareMarketsMoversGeneralBriefspremarket tradingwhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in